Suchergebnisse - "47M74X9YT5"

PubPharm (1.798)

1

Cladribine improves cutaneous manifestations, Dermatology Life Quality Index, and Mastocytosis Quality of Life of patients with mastocytosis

enthalten in: Journal of the American Academy of Dermatology | 2024

von Bugaut, H. | Maillard, H. | Jacobzone, C. | +8

2

Early clearance of hairy cell leukaemia in the bone marrow after first-line treatment with cladribine predicts a favourable outcome

enthalten in: British journal of haematology | 2024

von Ligia, S. | Passucci, M. | Assanto, G. | +7

3

Magnetic Resonance Imaging Evidence Supporting the Efficacy of Cladribine Tablets in the Treatment of Relapsing-Remitting Multiple Sclerosis

enthalten in: CNS drugs | 2024

von Cortese, R. | Testa, G. | Assogna, F. | +1

4

Headache in Multiple Sclerosis : A Narrative Review

enthalten in: Medicina (Kaunas, Lithuania) | 2024

von Adamczyk, B. | Morawiec, N. | Boczek, S. | +6

5

ABT199/venetoclax synergism with thiotepa enhances the cytotoxicity of fludarabine, cladribine and busulfan in AML cells

enthalten in: Oncotarget | 2024

von Valdez, B. | Yuan, B. | Murray, D. | +4

6

Incidence of SARS-CoV-2 infection in patients with multiple sclerosis who received SARS-CoV-2 vaccines and are under treatment with high-efficacy therapies in Argentina

enthalten in: Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology | 2024

von Carnero Contentti, E. | López, P. | Pappolla, A. | +28

7

Advanced systemic mastocytosis-Revised classification, new drugs and how we treat

enthalten in: British journal of haematology | 2024

von Pardanani, A. | Reichard, K. | Tefferi, A.

8

Quantifying the administration and monitoring time burden of several disease-modifying therapies for relapsing multiple sclerosis in the United Kingdom : A time and motion study

enthalten in: Multiple sclerosis and related disorders | 2024

von Rog, D. | Brownlee, W. | Carod-Artal, F. | +9

9

Efficacy and safety of autologous haematopoietic stem cell transplantation versus alemtuzumab, ocrelizumab, ofatumumab or cladribine in relapsing remitting multiple sclerosis (StarMS) : protocol for a randomised controlled trial

enthalten in: BMJ open | 2024

von Brittain, G. | Petrie, J. | Duffy, K. | +58

10

CSF levels of Chitinase3like1 correlate with early response to cladribine in multiple sclerosis

enthalten in: Frontiers in immunology | 2024

von Marastoni, D. | Foschi, M. | Eccher, C. | +16

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[180]